stockrow
Saturday 7 November 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +27.5%
- Free cash flow
- +938.8%
- Total debt
- +24.8%
Quarter to September 2026, against a year earlier
2.86
0.13
−4.35%
Follow ARDX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.45 | 3.44 | 2.81 | 1.83 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
67.07 | (45.68) | (197.71) | 393.84 | |
P/B ratio |
8.42 | 9.91 | 8.49 | 5.21 | |
Price to Tangible BV |
8.42 | 9.91 | 8.49 | 5.21 | |
EV/Sales |
3.36 | 3.43 | 2.80 | 1.81 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(32.26) | (40.40) | (72.87) | (54.73) | |
EV/FCF |
(31.16) | (39.07) | (70.44) | (53.21) | |
Quick Ratio |
3.80 | 2.93 | 2.89 | 2.96 | |
Current Ratio |
4.31 | 3.49 | 3.34 | 3.45 | |
Net Debt/EBITDA |
(10.27) | 1.08 | 2.54 | (7.10) | |
Debt/Assets |
40.44% | 40.34% | 43.73% | 42.95% | |
Debt/Equity |
1.21 | 1.37 | 1.69 | 1.54 | |
Asset Turnover |
0.87 | 0.94 | 0.86 | 0.87 | |
Operating CF/Net income |
(51.48) | 0.86 | 0.38 | (2.95) | |
Capex/Depreciation |
(0.39) | (0.08) | (0.02) | 0.00 | |
Interest Coverage |
0.67 | (4.74) | (2.00) | 0.55 | |
Research and Development Expense of Revenue |
18.25% | 21.37% | 21.59% | 19.74% | |
Selling, General and Administrative Expense of Revenue |
69.01% | 108.25% | 83.92% | 73.55% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
9.94% | 14.99% | 12.67% | 11.83% | |
Graham Net Nets |
0.03 | 0.02 | 0.01 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.36%) | (3.91%) | (4.39%) | (6.52%) | |
Free Cash Flow Yield |
(3.13%) | (2.55%) | (1.42%) | (1.87%) | |
Revenue per Share |
0.52 | 0.38 | 0.49 | 0.51 | |
Operating CF per Share |
0.09 | (0.13) | (0.03) | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.09 | (0.13) | (0.03) | 0.01 | |
Cash per Share |
1.10 | 0.97 | 1.14 | 1.14 | |
Shareholders Equity per Share |
0.69 | 0.60 | 0.60 | 0.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.69 | 0.60 | 0.60 | 0.66 | |
Free Cash Flow |
20.59 | (32.31) | (6.41) | 2.17 | |
Working Capital |
293.71 | 272.30 | 309.71 | 313.58 | |
Capital Expenditures |
(0.36) | (0.07) | (0.01) | 0.00 | |
Net Current Asset Value |
47.66 | 25.99 | 15.05 | 17.91 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
64.78 | 64.65 | 81.45 | 85.03 | |
Average Payables |
17.62 | 20.96 | 30.05 | 26.02 | |
Average Inventory |
19.45 | 23.26 | 24.07 | 24.81 | |
Average Assets |
468.68 | 457.35 | 521.33 | 536.85 | |
Average Common Equity |
170.12 | 147.15 | 144.27 | 159.16 |
Columns are period end dates · fundamentals updated 5 Nov 2026